150 related articles for article (PubMed ID: 22087319)
1. External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement.
Hajage D; de Rycke Y; Bollet M; Savignoni A; Caly M; Pierga JY; Horlings HM; Van de Vijver MJ; Vincent-Salomon A; Sigal-Zafrani B; Senechal C; Asselain B; Sastre X; Reyal F
PLoS One; 2011; 6(11):e27446. PubMed ID: 22087319
[TBL] [Abstract][Full Text] [Related]
2. Accuracy validation of adjuvant! online in Taiwanese breast cancer patients--a 10-year analysis.
Yao-Lung K; Dar-Ren C; Tsai-Wang C
BMC Med Inform Decis Mak; 2012 Sep; 12():108. PubMed ID: 22985190
[TBL] [Abstract][Full Text] [Related]
3. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.
Mook S; Schmidt MK; Rutgers EJ; van de Velde AO; Visser O; Rutgers SM; Armstrong N; van't Veer LJ; Ravdin PM
Lancet Oncol; 2009 Nov; 10(11):1070-6. PubMed ID: 19801202
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
5. Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy.
Synnestvedt M; Borgen E; Russnes HG; Kumar NT; Schlichting E; Giercksky KE; Kåresen R; Nesland JM; Naume B
Acta Oncol; 2013 Jan; 52(1):91-101. PubMed ID: 22934555
[TBL] [Abstract][Full Text] [Related]
6. Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67.
Kashiwagi S; Yashiro M; Takashima T; Aomatsu N; Ikeda K; Ogawa Y; Ishikawa T; Hirakawa K
Breast Cancer Res; 2011; 13(6):R122. PubMed ID: 22126395
[TBL] [Abstract][Full Text] [Related]
7. Validity of Adjuvant! Online program in older patients with breast cancer: a population-based study.
de Glas NA; van de Water W; Engelhardt EG; Bastiaannet E; de Craen AJ; Kroep JR; Putter H; Stiggelbout AM; Weijl NI; van de Velde CJ; Portielje JE; Liefers GJ
Lancet Oncol; 2014 Jun; 15(7):722-9. PubMed ID: 24836274
[TBL] [Abstract][Full Text] [Related]
8. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Cheang MC; Chia SK; Voduc D; Gao D; Leung S; Snider J; Watson M; Davies S; Bernard PS; Parker JS; Perou CM; Ellis MJ; Nielsen TO
J Natl Cancer Inst; 2009 May; 101(10):736-50. PubMed ID: 19436038
[TBL] [Abstract][Full Text] [Related]
9. An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom.
Campbell HE; Taylor MA; Harris AL; Gray AM
Br J Cancer; 2009 Oct; 101(7):1074-84. PubMed ID: 19724274
[TBL] [Abstract][Full Text] [Related]
10. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
11. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Nottingham Prognostic Index and Adjuvant Online prognostic tools in young women with breast cancer: review of a single-institution experience.
Hearne BJ; Teare MD; Butt M; Donaldson L
BMJ Open; 2015 Jan; 5(1):e005576. PubMed ID: 25628047
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant! Online is overoptimistic in predicting survival of Asian breast cancer patients.
Bhoo-Pathy N; Yip CH; Hartman M; Saxena N; Taib NA; Ho GF; Looi LM; Bulgiba AM; van der Graaf Y; Verkooijen HM
Eur J Cancer; 2012 May; 48(7):982-9. PubMed ID: 22366561
[TBL] [Abstract][Full Text] [Related]
14. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
[TBL] [Abstract][Full Text] [Related]
15. Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer.
Zhao Y; Yang N; Wang X; Huang Y; Zhou X; Zhang D
Clin Transl Oncol; 2020 Dec; 22(12):2275-2285. PubMed ID: 32447641
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
18. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
[TBL] [Abstract][Full Text] [Related]
19. Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer.
Fasching PA; Gass P; Häberle L; Volz B; Hein A; Hack CC; Lux MP; Jud SM; Hartmann A; Beckmann MW; Slamon DJ; Erber R
Breast Cancer Res Treat; 2019 Jun; 175(3):617-625. PubMed ID: 30868391
[TBL] [Abstract][Full Text] [Related]
20. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.
Criscitiello C; Disalvatore D; De Laurentiis M; Gelao L; Fumagalli L; Locatelli M; Bagnardi V; Rotmensz N; Esposito A; Minchella I; De Placido S; Santangelo M; Viale G; Goldhirsch A; Curigliano G
Breast; 2014 Feb; 23(1):69-75. PubMed ID: 24314620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
